You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?

You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?

You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine
American Diabetes Association